Next Article in Journal
Immunotherapy in Prostate Cancer
Previous Article in Journal
Treatment of Locally Advanced Gastric Cancer (LAGC): Back to Lauren’s Classification in Pan–Cancer Analysis Era?
Open AccessReview

Renal and Cardiovascular Toxicities by New Systemic Treatments for Prostate Cancer

1
Operative Unit of Medical Oncology, IRCCS Istituti Clinici Scientifici Maugeri, 27100 Pavia, Italy
2
Department of Internal Medicine and Therapeutics, University of Pavia, 27100 Pavia, Italy
3
Operative Unit of Translational Oncology, IRCCS Istituti Clinici Scientifici Maugeri, 27100 Pavia, Italy
4
Experimental Medicine School, University of Pavia, 27100 Pavia, Italy
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(7), 1750; https://doi.org/10.3390/cancers12071750
Received: 6 May 2020 / Revised: 19 June 2020 / Accepted: 25 June 2020 / Published: 1 July 2020
(This article belongs to the Special Issue Efforts to Mitigate the Toxicity of Cancer Therapeutics)
Prostate cancer (PC) is the most common male cancer in Western Countries. In recent years, the treatment of relapsed or metastatic disease had benefited by the introduction of a variety of new different drugs. In consideration of the relative long survival of PC patients, side effects of these drugs must be considered and monitored. In this review, we analyzed the newly developed therapies for PC treatment, describing the mechanism of action, the metabolism and latest clinical trials that led to the approval of these drugs in clinical practice. We then evaluated the cardiovascular and renal side effects from pivotal phase III and II studies and meta-analyses. Cardiovascular side effects are the most frequent, in particular hypertension, while renal toxicity is rarer and not well described in literature. Therefore, there is a need to better define the effects of these therapies, in order to personalize patient treatment on the basis of their comorbidities and preferences, in addition to their symptoms and disease load. View Full-Text
Keywords: abiraterone; apalutamide; cabazitaxel; darolutamide; enzalutamide; radium-223 abiraterone; apalutamide; cabazitaxel; darolutamide; enzalutamide; radium-223
MDPI and ACS Style

Saltalamacchia, G.; Frascaroli, M.; Bernardo, A.; Quaquarini, E. Renal and Cardiovascular Toxicities by New Systemic Treatments for Prostate Cancer. Cancers 2020, 12, 1750.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop